At a glance
- Originator Pfizer
- Class Antiparasitics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Trichostrongylosis
Most Recent Events
- 15 Jul 2011 Discontinued - Preclinical for Trichostrongylosis in United Kingdom (unspecified route)
- 27 Jul 2000 Profile reviewed but no significant changes made
- 23 Jun 2000 Pfizer has merged with Warner-Lambert